A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

PURPOSE: Angiogenesis inhibition has emerged as a potentially promising treatment strategy for neuroendocrine tumors. 2-Methoxyestradiol (2ME2; Panzem®) is a natural derivative of estradiol with demonstrated anti-angiogenic activity in animal models. We performed a prospective, phase II study of 2ME...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kulke, Matthew H., Chan, Jennifer A., Meyerhardt, Jeffrey A., Zhu, Andrew X., Abrams, Thomas A., Blaszkowsky, Lawrence S., Regan, Eileen, Sidor, Carolyn, Fuchs, Charles S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3955980/
https://ncbi.nlm.nih.gov/pubmed/20960192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1478-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak